Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Looks To Resume Unannounced Inspections In India And China

Dec 16 2021

• By Shannon Brown

• Source: Alamy

Related Content

US Forming Industry Consortia To Prepare For Future Pandemics And Global Supply Chain Disruptions

Dec 01 2021

US FDA’s In-Person Foreign Inspections Remain On House Appropriators’ Minds

Jul 07 2021

US FDA Resumes China, India Inspections In Bid To Keep Drug Approvals On Schedule

Jan 27 2021

India’s COVID-19 Surge Forced Another Abrupt Stop Of US FDA In-Person Inspections

May 21 2021

Senators Press For More Surprise Drug GMP Inspections Abroad

Jun 04 2020

Real-Time Manufacturing Volume Reporting Could Help Prevent Drug Shortages, Woodcock Tells Congress

Oct 31 2019

Confronting Illusions of Quality in Indian Generics Manufacturing

Mar 28 2014

Additional Topics

Asia Pacific China India Europe International Middle East and Africa United States South America Coronavirus COVID-19 FDA Enforcement Compliance Consumer Commercial Dietary Supplements Ingredients Manufacturing OTC Drugs Policy Regulation

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window